– UK, Oxford – Oxford Nanopore Technologies plc (LON: ONT), the company delivering a new generation of nanopore-based molecular sensing technology, announced the appointment of Dr.Daniel Mahony to its Board as a Non-Executive Director effective from 1st October 2024, bringing extensive sector experience to help accelerate Oxford Nanopore’s commercial traction, with more than 25 years as a global healthcare investor specializing in biotechnology, medical technology and healthcare services.
“We are extremely pleased to welcome Daniel to the board as Non-Executive Director of Oxford Nanopore. Daniel’s deep knowledge of the biopharma sector, combined with his understanding of Oxford Nanopore’s opportunity to drive value across the biopharma development pipeline, position him as an ideal source of expertise to support the company’s commercial expansion into this space,” said Board Chair, Duncan Tatton-Brown.
Dr Guy Harmelin who has served on the Board since 2020, will step down from the Board with effect from today.
About Dr. Daniel Mahony
DDr.Daniel Mahony is a Senior Partner in Growth Investments at Novo Holdings and will serve as a critical sounding board to the Group as it continues to advance its technology platform to address a significant commercial opportunity in biopharmaceuticals. Dr.Daniel Mahony chairs the UK BioIndustry Association and is a Non-Executive Director of the Wellcome Sanger Institute.
Prior to joining Novo Holdings, Dr.Daniel Mahony co-founded the healthcare business unit at Polar Capital in London, growing it to more than $4 billion in assets under management. He was formerly a Senior Research Analyst at Morgan Stanley in London, an Analyst at ING Barings Furman Selz in New York, and completed his postdoctoral work at DNAX Research Institute in Palo Alto.
Dr. Daniel Mahony said: “This is an exciting time for Oxford Nanopore with its expanding opportunity in biopharma, where rapid sequencing, richer data and a streamlined platform can support discovery and delivery of new biopharmaceuticals. I look forward to bringing my industry expertise to bear as Oxford Nanopore executes against its exciting growth plans in this sector.”
Novo Holdings is a shareholder in Oxford Nanopore and led the recent £80 million equity placing.
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore’s technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more: https://nanoporetech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.